Gujarat Kidney & Super Speciality IPO Details 2025 | Price Band, Dates & Review
Gujarat Kidney & Super Speciality IPO – Price Band, Dates, GMP, Financials & Company Review (2025)
Educational article by Money Bells Research Analyst (SEBI RA – INH100009901)
Gujarat Kidney & Super Speciality – Company Overview
Gujarat Kidney & Super Speciality Limited is a Gujarat-based healthcare services provider operating multi-speciality hospitals with a strong focus on renal care, urology, nephrology, dialysis and critical care services.
The company caters to patients requiring long-term treatment for kidney-related diseases, which makes the business relatively non-cyclical compared to other sectors.
IPO Details
| IPO Type | Mainboard IPO (Book Built Issue) |
|---|---|
| Listing Exchange | BSE & NSE |
| Issue Size | Approx. ₹225 crore |
| Fresh Issue | 2.20 crore equity shares |
| Offer for Sale (OFS) | Nil |
| Face Value | ₹2 per share |
| Registrar | MUFG Intime India Pvt. Ltd. |
| Lead Manager | Nirbhay Capital Services Pvt. Ltd. |
Price Band & Lot Size
| Price Band | ₹97 – ₹102 per share |
|---|---|
| Lot Size | 147 shares |
| Minimum Investment | ₹14,994 (at upper band) |
Important Dates
| IPO Opens | 22 December 2025 |
|---|---|
| IPO Closes | 24 December 2025 |
| Basis of Allotment | 26 December 2025 |
| Refunds / Demat Credit | 29 December 2025 |
| Listing Date | 30 December 2025 |
Use of IPO Proceeds
- Acquisition of existing hospitals
- Capital expenditure for new hospital facilities
- Purchase of advanced medical equipment
- Repayment of certain borrowings
- General corporate purposes
Business Model
The company follows a hospital-based healthcare delivery model and earns revenue from in-patient treatments, dialysis services, surgeries, consultations and diagnostics.
Financial Snapshot
| Revenue (FY24) | ₹18.7 crore |
|---|---|
| Profit After Tax | ₹5.6 crore |
| Total Hospitals | 6 |
| Operational Beds | ~250 beds |
IPO GMP (Grey Market Premium)
As of the latest available data, Gujarat Kidney & Super Speciality IPO GMP is around ₹15–₹18 per share. GMP is unofficial and can change rapidly based on market sentiment.
Growth Drivers
- Rising incidence of kidney-related diseases
- Increasing healthcare spending in India
- Limited organised renal care players
- Expansion of hospital capacity
Risk Factors
- High operating and staffing costs
- Regulatory and healthcare compliance risks
- Dependence on skilled medical professionals
- SME-to-mainboard transition execution risk
⚠️ Apply karne se pehle FREE Trade Reports zarur check karein.
Investor Checklist
- Price band & valuation samjhein
- Healthcare sector risks evaluate karein
- Sirf GMP ke base par decision na lein
- Portfolio diversification zaruri hai
Disclosure (SEBI Compliance)
Important: This article is for educational purposes only.
Money Bells Global Research Services Pvt. Ltd. is a SEBI Registered Research Analyst (INH100009901). No buy or sell recommendation is made. IPO investments are subject to market risks. https://moneybells.in/resources/disclosure
Please read the Red Herring Prospectus carefully before investing.
.jpg)